File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium

TitleUnique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium
Authors
Issue Date2001
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2001, v. 19 n. 20-22, p. 2945-2954 How to Cite?
AbstractA novel vaccine for hepatitis B virus (HBV) was designed by putting a naked DNA vaccine carrying hepatitis B surface antigen (HBsAg) into live-attenuated Salmonella typhimurium. Mucosal immunization by the oral route in mice showed significantly stronger cytotoxic T lymphocyte (CTL) response than recombinant HBsAg vaccination (P < 0.01 at an effector:target ratio of 100:1), while comparable to intramuscular naked DNA immunization at all effector:target ratios. Contrary to previous reports on naked DNA vaccines given intramuscularly, the IgG antibody response induced by the mucosal DNA vaccine is relatively weak when compared to recombinant HBsAg vaccine (P < 0.001 at day 21). These findings are supported by a high interferon-γ but a low interleukin-4 level detected in the supernatant of splenic cell cultures obtained from mucosally immunized mice. As distinct to recombinant HBsAg vaccine which is effective for protection, oral mucosal DNA vaccine should be considered as a candidate for therapeutic immunization in chronic HBV infection, donor immunization before adoptive transfer of HBV-specific CTL to HBsAg positive bone marrow transplant recipients, and immunization of non-responders to recombinant HBsAg vaccine. This strongly cellular and relatively absent humoral response may make this vaccine a better candidate as a therapeutic vaccine for chronic HBV carriers than naked DNA vaccines, as the humoral response is relatively less important for the clearance of HBV from hepatocytes, but its presence may lead to side effects such as serum sickness and immune complex deposition in chronic HBV carriers. © 2001 Elsevier Science Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/79003
ISSN
2015 Impact Factor: 3.413
2015 SCImago Journal Rankings: 2.044
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWoo, PCYen_HK
dc.contributor.authorWong, LPen_HK
dc.contributor.authorZheng, BJen_HK
dc.contributor.authorYuen, KYen_HK
dc.date.accessioned2010-09-06T07:49:25Z-
dc.date.available2010-09-06T07:49:25Z-
dc.date.issued2001en_HK
dc.identifier.citationVaccine, 2001, v. 19 n. 20-22, p. 2945-2954en_HK
dc.identifier.issn0264-410Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/79003-
dc.description.abstractA novel vaccine for hepatitis B virus (HBV) was designed by putting a naked DNA vaccine carrying hepatitis B surface antigen (HBsAg) into live-attenuated Salmonella typhimurium. Mucosal immunization by the oral route in mice showed significantly stronger cytotoxic T lymphocyte (CTL) response than recombinant HBsAg vaccination (P < 0.01 at an effector:target ratio of 100:1), while comparable to intramuscular naked DNA immunization at all effector:target ratios. Contrary to previous reports on naked DNA vaccines given intramuscularly, the IgG antibody response induced by the mucosal DNA vaccine is relatively weak when compared to recombinant HBsAg vaccine (P < 0.001 at day 21). These findings are supported by a high interferon-γ but a low interleukin-4 level detected in the supernatant of splenic cell cultures obtained from mucosally immunized mice. As distinct to recombinant HBsAg vaccine which is effective for protection, oral mucosal DNA vaccine should be considered as a candidate for therapeutic immunization in chronic HBV infection, donor immunization before adoptive transfer of HBV-specific CTL to HBsAg positive bone marrow transplant recipients, and immunization of non-responders to recombinant HBsAg vaccine. This strongly cellular and relatively absent humoral response may make this vaccine a better candidate as a therapeutic vaccine for chronic HBV carriers than naked DNA vaccines, as the humoral response is relatively less important for the clearance of HBV from hepatocytes, but its presence may lead to side effects such as serum sickness and immune complex deposition in chronic HBV carriers. © 2001 Elsevier Science Ltd.en_HK
dc.languageengen_HK
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_HK
dc.relation.ispartofVaccineen_HK
dc.rightsVaccine. Copyright © Elsevier Ltd.en_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHepatitis B Surface Antigens - genetics - immunologyen_HK
dc.subject.meshHepatitis B Vaccines - immunologyen_HK
dc.subject.meshInterferon-gamma - biosynthesisen_HK
dc.subject.meshInterleukin-4 - biosynthesisen_HK
dc.subject.meshMiceen_HK
dc.subject.meshMice, Inbred BALB Cen_HK
dc.subject.meshSalmonella typhimurium - genetics - immunologyen_HK
dc.subject.meshT-Lymphocytes, Cytotoxic - immunologyen_HK
dc.subject.meshTransfectionen_HK
dc.subject.meshVaccines, Attenuated - immunologyen_HK
dc.subject.meshVaccines, DNA - immunologyen_HK
dc.subject.meshVaccines, Synthetic - immunologyen_HK
dc.titleUnique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimuriumen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0264-410X&volume=19&spage=2945&epage=2954&date=2001&atitle=Unique+immunogenicity+of+hepatitis+B+virus+DNA+vaccine+presented+by+live-attenuated+Salmonella+typhimuriumen_HK
dc.identifier.emailWoo, PCY:pcywoo@hkucc.hku.hken_HK
dc.identifier.emailZheng, BJ:bzheng@hkucc.hku.hken_HK
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_HK
dc.identifier.authorityWoo, PCY=rp00430en_HK
dc.identifier.authorityZheng, BJ=rp00353en_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0264-410X(00)00530-2en_HK
dc.identifier.pmid11282206-
dc.identifier.scopuseid_2-s2.0-0035815502en_HK
dc.identifier.hkuros61960en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035815502&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume19en_HK
dc.identifier.issue20-22en_HK
dc.identifier.spage2945en_HK
dc.identifier.epage2954en_HK
dc.identifier.isiWOS:000167799900022-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridWoo, PCY=7201801340en_HK
dc.identifier.scopusauthoridWong, LP=7402092221en_HK
dc.identifier.scopusauthoridZheng, BJ=7201780588en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats